576results about How to "Good immune protection" patented technology

The invention relates to a gene deletion attenuated African swine fever virus as a vaccine and the vaccine, and a construction method thereof. An African swine fever Chinese epidemic strain Pig/CN/HLJ/2018 is adopted, a virulence gene of the African swine fever virus is deleted by a genetic engineering technology, and the gene deletion virus of MGF360-505R deletion and joint deletion of CD2V and MGF360-505R is obtained. Experiments show that the two virus strains can provide 100% immune protection against the African swine fever Chinese epidemic virulent strains, can be used as vaccines for safe and effective prevention and control of African swine fever in China, and have great social value.

Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.

A cyclic dinucleotide compound of Formula (I):

wherein X₁ is H or F; X₂ is H or F; at least one among X₁ and X₂ is a fluorine atom; Z is OH, OR₁, SH or SR₁, wherein: R₁ is Na or NH₄, or R₁ is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B₁ and B₂ are bases chosen from Adenine, Hypoxanthine or Guanine, and B₁ is a different base than B₂ and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.

The invention mainly aims to provide a porcine circovirus type 2 (PCV2) subunit vaccine and a preparation method thereof. Particularly, a baculovirus vector expression system is utilized to express a large amount of recombinant open reading frame type 2 (ORF2) protein in insect cells, so that the subunit vaccine with good immunity effect is developed. A bac-to-bac baculovirus expression system is adopted to perform whole gene amplification on the porcine circovirus type 2 ORF2 gene, and a melittin signal peptide nucleotide sequence is introduced into a terminal 5', so that the recombinant baculovirus of an open reading frame containing the melittin signal peptide nucleotide sequence and a PVC2ORF2 gene sequence is established, wherein the infected insect cell expresses the recombinant ORF2 protein with efficient and high PCV2 antigenicity; and thus the subunit vaccine containing the PCV2 recombinant ORF2 protein is prepared. The inoculation experiments of piglets show that the subunit vaccine has a good immunity protection effect.

The present invention relates to an artificially synthesized gene optiHA containing codons for chicken partial tropism. Its reading frame contains 1707 bp nucleotides and encodes a total of 568 amino acids. The gene is compatible with H5 subtype highly pathogenic avian influenza virus A/ Goose/GuangDong/1/96(H5N1)[GD/1/96(H5N1)]hemagglutinin (HA) gene has a nucleotide homology rate of 70%, an amino acid homology rate of 100%, and encodes the H5 subtype Hemagglutinin (HA) protein of avian influenza virus GD/1/96 (H5N1). The invention also relates to the application of the gene as an immunogenic gene of H5 subtype influenza DNA vaccine and other genetic engineering vaccines.

The present invention provides one kind of genetic engineering multivalent subunit vaccine for preventing and treating human helicobacter pylori infection and its preparation process. The vaccine consists of active helicobacter pylori UreB fragment UreB414 as the central antigen component, other combined protective antigens, and intramolecular or extramolecular adjuvant. Compared with univalent vaccine, the multivalent combined vaccine can stimulate the body to generate more powerful and more comprehensive helicobacter pylori resisting specific immune reaction.

The invention belongs to the field of molecular biology, and discloses a porcine circovirus type 2 recombinant cap protein and a subunit vaccine. The porcine circovirus type 2 cap protein expressed by recombinant Escherichia coli is obtained by steps of cloning a porcine circovirus type 2 cap protein in a nuclear localization signal area of which the N terminal is cut and which is rich in arginine into a prokaryotic expression vector to obtain a recombinant expression vector, transfecting the recombinant expression vector into Escherichia coli BL21(DE3), and expressing by using the recombinant Escherichia coli BL21(DE3). Tests prove that the constructed recombinant strain expresses a foreign protein stably. When the subunit vaccine is prepared from the expressed recombinant protein, an antigen has high purity and safety, does not have pathogenicity on animals such as pigs and the like, and passes safety evaluation easily.

The invention relates to a 2 type subunit vaccine for a porcine circovirus as well as a preparation method and application thereof. A recombinant bacilliform virus contains double promoters (a polyhedrin promoter and a P10 promoter), a coding gene of a Cap protein with double copying can be expressed, and the expression efficiency of the protein is obviously enhanced; moreover, the Cap protein expressed by an inserted foreign gene does not contain an excess sequence, virus-like particles (VLPs) can be effectively formed, and the immunogenicity of an expressed protein is enhanced; furthermore, a produced antigen has high content; and according to the 2 type subunit vaccine for the porcine circovirus, which is disclosed by the invention, the productivity ratio and the quality of a viral protein of the 2 type subunit vaccine for the porcine circovirus are obviously enhanced, and a prepared vaccine composition has the advantages of stable and persistent immune effect, high safety and the like.

The invention discloses a SARS vaccine and preparing method, which comprises the following steps: 1) constructing external baculoviral surface display carrier of S protein of SARS coronary virus; 2) transmitting the carrier into susceptive cell with baculoviral genome plasmid Bacmid; obtaining recombinant baculoviral genome plasmid; 3) using the plasmid to infect insect cell; purifying the recombinant plasmid; obtaining the product.

The invention discloses a foot-and-mouth disease genetic engineering mixed epitope vaccine and a preparation method thereof. The vaccine consists of the following four parts: a serial B cell epitope recombinant protein BI consisting of main neutralizing epitops of O-type foot-and-mouth disease viruses in Cathay, Transasia and Mya 98 pedigrees with a gene sequence of SEQ ID NO:1 and an amino acid sequence of SEQ ID NO:2, a T-cell epitope recombinant protein TI consisting of serial connection of universal T-cell epitope and a plurality of foot-and-mouth disease virus specific T-cell epitopes with a gene sequence of SEQ ID NO:3 and an amino acid sequence of SEQ ID NO:4, Toll-like receptor 3 agonist-polyinosinic acid-polycytidysic acid and/or Toll-like receptor7/8 agonist-R848 serving as immunopotentiator, and 201 oil adjuvant. When being used for immunizing a pig, the BI and TI mixed epitope vaccine prepared by utilizing the method can produce a protective immunization effect the same as or better than that of an inactivated influenza virus Vaccines, and has a cross protection effect to viruses of the three pedigrees, so that the vaccine is a novel immune-enhanced O-type foot-and-mouth genetic engineering mixed epitope vaccine.

The invention discloses an avian infectious bronchitis cold adaptation attenuated vaccine strain and application thereof. In the invention, an avian infectious bronchitis virus wild strong strain is subject to continuous low-temperature cold adaption passage attenuated culture so as to obtain a cold adaption weak virus vaccine strain with good immune protective efficiency, and the microbial preservation number is CGMCC No.4711. Immune efficiency evaluation experiments show that the cold adaptation attenuated vaccine strain disclosed by the invention has good immune protectiveness, the active immune protection rate is over 80%, the passive immune can get over 90% protection within 9 days, and the cold adaptation attenuated vaccine strain has good protective efficiency to avian infectious bronchitis, and can effectively protect chicken against the attack of the virulence of avian infectious bronchitis viruses. Safety experiments show that the cold adaption weak virus live vaccine disclosed by the invention is safe for chickens and layer chickens, has no side effects and has good safety. The cold adaption attenuated vaccine strain can be applied in the preparation of single vaccine or combined vaccine and the like for preventing the avian infectious bronchitis viruses.

The invention relates to an application of brucellosis A19 molecular marking vaccine and immunological identification of the brucellosis A19 molecular marking vaccine. The brucellosis vaccine can be applied to an enzyme-linked immunosordent assay (iELISA) method to distinguish an animal inoculated with the vaccine from a wild virus infected animal. According to the invention, a cattle is used as a test target animal antiepidemic to the brucellosis, the cattle is immune to brucellosis A19-detlaVirB12 marking vaccine so as to evaluate the immunological protection of the molecular marking vaccine. An iELISA method for distinguishing the brucellosis A19-detlaVirB12 immune animal from the wild virus infected animal is created. The brucellosis A19-detlaVirB12 marking vaccine provided by the invention not only has good immunological protection against the cattle brucellosis, and the iELISA method provided by the invention solves the problem that the immune animal is difficult to be distinguished from the clinic diseased animal, and the brucellosis A19 molecular marking vaccine has an actual application value in prevention and control, elimination and purification of the cattle brucellosis.

The invention belongs to the technical field of biological medicines for veterinary use and in particular relates to a largemouth bass iridovirus disease inactivated vaccine and a preparation method thereof. The vaccine comprises EPC (epithelioma papulosum cyprinid) cells and largemouth bass ranavirus LMBV. The preparation method comprises the following steps: culturing EPC cells; performing LMBVvirus amplification on the cultured EPC cells so as to obtain an LMBV virus liquid; and performing inactivation treatment on the LMBV virus liquid. The vaccine prepared by the invention is good in immune protection effect and can be applied to prophylactic immunization of largemouth bass iridovirus, and the survival rate and the breeding benefits of largemouth bass can be increased.

The invention discloses a porcine circovirus-like particle, a vaccine and a preparation method thereof. The virus-like particle is composed of a main structural protein-nucleocapsid protein of 2-type porcine circovirus, can excite cell and humoral immune response, can be used as a virus-like particle vaccine (VLP vaccine) to immune different fauna and can safely and effectively prevent PCV-2 infections after being used. The VLP can be made into injections, nose drops and drinking preparations by adding adjuvants or not. An ideal vaccine is provided for security of different populations of sows, piglets, fattening pigs and for effective immune prevention and control of PCV-2 infections.

The invention discloses a preparation method and an application of a recombinant cold-adaptation attenuated influenza vaccine strain. The method comprises the following steps: importing an influenza virus hemagglutinin HA gene, an influenza virus neuraminidase NA gene as well as seven genes, namely PB2, PB1, PA, NP, M, NS1 and NS2, in an influenza virus to a host cell, and conducting cultivating, so that a recombinant virus is obtained. Tests prove that an attenuated influenza tetravalent vaccine, which is prepared by virtue of a 7+2 plasmid rescuing system, can achieve an excellent immune effect through nasal immunization; the influenza virus, which is recombined by the 7+2 plasmid rescuing system, has a property of being time-efficient; in accordance with the epidemic characteristics of influenza viruses in various years, effective targeted influenza vaccines can be prepared; and the preparation method is rapid, obvious in immunogenicity and immune protection effect, and good in safety; therefore, the problems on safety and stability of attenuated influenza vaccines which are prepared by virtue of a conventional method are solved, and a protection spectrum of the influenza vaccines is more comprehensive.

The invention discloses an antibiotic-free piglet feed and a preparation method thereof, and belongs to the fields of formula design and processing technologies of feeds. The feed is mainly prepared from, by weight, 50-60 parts of corn, 2-4 parts of steamed fish meal, 10-16 parts of soybean meal, 1-5 parts of puffed soybeans, 3-5 parts of wheat flour, 3-6 parts of whey powder, 0.5-1 part of coconut oil, 0.5-1 part of soybean oil, 0.02-0.03 parts of antibacterial peptides, 1-3 parts of probiotics, 0.012 parts of Yucca smalliana Fern. extract, 0.3-0.7 parts of stone flour, 0.3-0.5 parts of edible salt, 0.8-1.2 parts of calcium hydrogen phosphate, 0.3-0.8 parts of amino acids, 0.03-0.05 parts of compound enzyme, 0.3-0.4 parts of composite vitamins and 0.2-0.6 parts of composite trace elements. The feed meets antibiotic-free piglet daily ration nutrient standards, adopts the antibacterial peptides to substitute antibiotics, and comprehensively solves problems through adding the probiotics, the daily gain is increased by 6.17%, the average daily feed intake is increased by 5.38%, and the diarrhea rate is reduced by 8.72%. The feed makes the intestinal tracts of piglets have good health state, has high disease resistance, and lays an early foundation for early slaughtering, no medication and safe pork products.

The invention relates to an adjuvant for improving the immunization effect of Edwardsiella vaccine and a use method of the adjuvant. The adjuvant is characterized by being extracted from raw materials including grain, yeast and a part of fungi or algae. The effective component of the adjuvant is beta-1,3-glucan or the natural, artificially modified or synthetic product of the beta-1,3-glucan. The adjuvant can be used for increasing the specific immune protection ratio of any one or more inculcated Edwardsiella vaccine antigens including the inactivated bacteria, the bacteria disintegration component, the less-virulent strain, the attenuated strain, the protective antigen, the antigen subunit, the antigenic determinant clusters or the expression product of the antigen cell expression vector of the Edwardsiella, can be used together or not together with the vaccine antigen and can be prepared into a single preparation which is used together with the vaccine antigen.

This invention discloses attenuated Brucella mutant, its construction method and its application. The attenuated Brucella mutant is constructed by deleting bp26, wboA, omp31, and P39 or pgm gene from attenuated Brucella. It is proven by experiments that attenuated Brucella mutant has good immune protection effects and the same virulence as attenuated Brucella. Because certain antigen is delected in the attenuated Brucella mutant, vaccine immunity and natural infection can be differentiated according to the immunobiology of the deleted gene. The attenuated Brucella mutant can be used to manufacture preventative Brucella vaccine and marked attenuated vaccine, and prevent epidemic diseases caused by Brucella.

The invention relates to a bivalent vaccine composition for resisting swine fever virus and porcine circovirus 2 infection, and preparation and application thereof. According to the method, a porcine circovirus 2 subunit antigen and a swine fever virus antigen are mixed and lyophilized to prepare the bivalent vaccine composition for resisting swine fever virus and porcine circovirus 2 infection; or a porcine circovirus 2 totivirus antigen inactivated vaccine is used as a diluent to dilute a swine fever virus vaccine, so as to prepare a bivalent vaccine composition kit for resisting swine fever virus and porcine circovirus 2 infection. The bivalent vaccine composition does not produce immunity interference; after immunization, the swine fever virus antigen speeds up in immunoreaction; the protective antibodies provided by the vaccine composition reach an immunization protective dose one week earlier than a single vaccine antibody; and the antibodies produced by the porcine circovirus vaccine in the bivalent vaccine have similar effects as that produced by single vaccine immune. The method has the advantages of simple vaccine production process and high production efficiency. The animal experiments prove that the effect of the vaccine composition is better that that of single vaccine immune, therefore the invention has great application value.

The invention discloses a poly valency fuse type enterorrhagia property bacillus coli O157:H7 gene engineering vaccine, which comprises the following steps: adopting enterorrhagia property bacillus coli O157:H7 Vi antigen Shiga's toxin II; combining subunit, compact sticking element and III type secretory protein A; constructing fuse engineering bacteria through gene retooling method; proceeding high density ferment; proceeding a series of purity course; getting fuse protein molecule vaccine with high purity. This invention possesses simple craft, good repeatability and higher protein purity.